MedTrace Logo

Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults

NCT01224067 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-04-18

No results posted yet for this study

Summary

This is a 16-week research study in which participants suffering from Social Anxiety Disorder (SAD) will receive Sertraline (a medication FDA approved for the treatment of SAD) for the first 8 weeks. If a participant remains symptomatic, he/she will enter the second phase of the study in which he/she continues taking Sertraline but also randomly receives either Seroquel or placebo in conjunction with Sertraline for additional 8 weeks. The purpose of this study is to determine the efficacy of adjunctive Seroquel in treating SAD.

Conditions

Interventions

DRUG

Quetiapine

Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Cambridge Health Alliance

    lead OTHER

Principal Investigators

  • Gustavo D Kinrys, MD · Cambridge Health Alliance; Harvard Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-07-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01224067 on ClinicalTrials.gov